Targeted Genetics Corp.
1100 Olive Way
Suite 100
Seattle,
WA 98101
United States - Map
Phone: 206-623-7612
Fax: 206-223-0288
Web Site: http://www.targen.com
| Targeted Genetics Corporation, a clinical-stage biotechnology company, engages in the research and development of gene therapy products and technologies for treating acquired and inherited diseases. Its products include rAAV1-SERCA2a, a Phase I/II clinical trial product used for the treatment of heart failure; and tgAAC09, an adeno-associated virus prophylactic vaccine candidate, which is in Phase I and Phase II clinical trials to protect against the progression of human immunodeficiency virus infection to AIDS. The companys products also comprise tgAAC94, which is in Phase II trials for the treatment of inflammatory arthritis, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; RNAi for the treatment of Huntingtons disease; and Inhibition of NADPH oxidase, which is in preclinical stage used for the treatment of amyotrophic lateral sclerosis. The company has collaborative and license agreements with Sirna Therapeutics, Celladon Corporation, International AIDS Vaccine Initiative, National Institute of Allergy and Infectious Diseases, and Amsterdam Molecular Therapeutics B.V. Targeted Genetics Corporation was founded in 1989 and is based in Seattle, Washington. |
|
| Key Statistics |
| |
| | Pay | Exercised | Ms. B.G. Susan Robinson , 48
Chief Exec. Officer, Pres |
$
257.00K | N/A | Mr. David J. Poston , 46
Chief Financial Officer, Principal Accounting Officer, VP of Fin., Sec. and Treasurer |
N/A
| N/A | Dr. Pervin Anklesaria Ph.D, 51
VP of Product Devel. |
N/A
| N/A | Dr. Ralph W. Paul Ph.D,
Director of Technology Evaluation |
N/A
| N/A | Dr. Richard W. Peluso , 56
VP of Process Sciences and Manufacturing |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
2.03% Nasdaq 
0.01 (4.17%) 
Profile
